---
title: "Aave V3 vs Compound III vs Morpho Blue: Lending Integration"
seoTitle: "Aave V3 vs Compound III vs Morpho Blue: Integration"
description: "Compare pooled reserves, base-asset markets and isolated lending markets in Aave V3, Compound III and Morpho Blue before designing an integration."
date: "2026-11-06"
reviewedDate: "2026-11-06"
reviewedLabel: "November 6, 2026"
reviewedBy: "FluidRWA Research Team"
readerFirst: "true"
readerImage: "true"
category: "DeFi Infrastructure"
slug: "aave-v3-vs-compound-iii-vs-morpho-blue-lending-integration"
image: "/assets/blog-thumbnails/lending-november5.webp"
socialImage: "/assets/blog-thumbnails/lending-november5.webp"
imageLocked: "true"
imageAlt: "Conceptual illustration of separate lending channels and control valves beside a risk-review tablet, not a protocol interface"
answer: "Compare Aave V3 at the reserve and pool level, Compound III at the base-asset market level, and Morpho Blue at the isolated market level. The integration decision depends on collateral behavior, parameter control, oracle assumptions and withdrawal liquidity. No protocol is ranked by yield or safety here."
considerationAfterTable: "true"
ctaTitle: "Planning a lending integration?"
ctaText: "Share the chain, asset and operational controls your integration needs, or email contact@fluidrwa.com."
ctaLabel: "Submit requirements"
ctaUrl: "/submit-requirement?source=article&article=aave-v3-vs-compound-iii-vs-morpho-blue-lending-integration"
ctaSecondaryLabel: "Email FluidRWA"
ctaSecondaryUrl: "mailto:contact@fluidrwa.com"
faq1q: "Does this comparison cover Aave V4 or Morpho Midnight?"
faq1a: "No. It deliberately compares Aave V3, Compound III and Morpho Blue. Later architectures and curated vault products require separate deployment-specific review."
faq2q: "Does supplied collateral always earn interest?"
faq2a: "No. Compound III distinguishes interest-earning base-asset supply from collateral used to borrow that asset. Do not apply one protocol's balance and interest model to another."
faq3q: "Is this a recommendation to deposit funds?"
faq3a: "No. This is an integration architecture comparison, not investment advice, a yield ranking or a finding that any market is suitable for a particular investor. No live positions were opened."
---

## Start with the balance your application promises to show

A product screen that displays one 'available balance' can hide three different questions: what the user supplied, what supports a loan and what can be withdrawn now. Before integrating a lending protocol, decide how the application will represent each one. A rate comparison cannot resolve an accounting or risk-model mismatch.

This review is deliberately scoped to Aave V3, Compound III and Morpho Blue. It does not treat all products carrying those brands as interchangeable. Aave's documentation now also covers V4, while Morpho documents vaults and Midnight separately. Pin the exact chain, deployment address, version and market before using any documentation in an implementation. Official references were reviewed November 6, 2026; no deposit, borrowing, liquidation or performance benchmark was executed.

| Integration decision | Aave V3 | Compound III | Morpho Blue |
|---|---|---|---|
| Primary unit to identify | Deployment, pool and asset reserve | Comet market and its base asset | Isolated market ID and full parameter tuple |
| Balance distinction | Supply, collateral use and debt | Base-asset supply versus collateral balances | Loan-asset supply, collateral and borrow shares |
| Risk configuration to inspect | Reserve caps and collateral settings | Asset configurations and market parameters | Loan token, collateral token, oracle, IRM and LLTV |
| Change question | Which governance or delegated action changes this reserve? | Which configured or upgradeable elements can change? | Which fixed market did we select, and what dependencies remain? |
| Withdrawal question | Is enough unborrowed liquidity available? | What base-asset liquidity and collateral constraints apply? | What liquidity remains in this market? |

The table is a map for investigation, not a complete feature inventory. Use the [Aave FAQ](https://www.aave.com/faq), [Compound III documentation](https://docs.compound.finance/) and [Morpho Blue market-creation reference](https://docs.morpho.org/curate/tutorials-market-v1/creating-market/) as starting records. The proposed operating tests below are FluidRWA analysis.

## Aave V3: make reserve configuration part of the application state

Aave's FAQ describes supply caps and states that withdrawals require sufficient unborrowed liquidity. The [protocol changelog](https://www.aave.com/docs/resources/changelog) records the introduction of efficiency mode, isolation mode and caps in V3. The [V3 market data reference](https://www.aave.com/docs/aave-v3/markets/data) marks isolation mode settings deprecated in V3.7. Verify the revision and configuration of the exact market rather than assuming every V3 deployment uses the same controls.

For an integration, keep asset identifiers separate from display symbols. A supported symbol on one network is not proof that another deployment uses the same token contract or risk configuration. Your review record should identify the deployment and reserve, then show the current settings used by the application. A cached list of symbols is insufficient.

Consider a synthetic user who supplies an asset and later uses part of the position to support borrowing. The interface should explain why a withdrawal that was possible before the loan may now be constrained. The support team needs to distinguish insufficient market liquidity from a position-health restriction and from a failed RPC request. Those are different incidents with different next steps.

Ask who watches parameter changes. An integration can remain technically online while its assumptions become stale. Define a review trigger for a cap, collateral or oracle-related change, and decide which user actions should pause pending review. A governance announcement is an input to that process; it is not proof that your application's cached state has been refreshed.

## Compound III: the base asset changes the bookkeeping

Compound III's [collateral and borrowing documentation](https://docs.compound.finance/collateral-and-borrowing/) distinguishes supplying the base asset to earn interest from supplying collateral to support borrowing. Collateral assets do not earn interest in that model. The direct documentation URL redirected and could not be read by the web tool during this review; the official indexed documentation and the accessible reference pages were used. Verify the current canonical documentation and deployed contract before implementation.

The consequence for a product team is immediate: a 'supplied assets' total cannot be labeled an interest-bearing total without checking the asset's role. Keep base supply, debt and collateral quantities separate in the data model. A user who deposits collateral should not see the base-asset supply rate attached to that balance merely because both actions are called supply.

Use [Compound's governance documentation](https://github.com/compound-finance/compound-finance.github.io/blob/master/docs/pages/v3/governance.md) as a reference for the selected market and its documented parameters. A deployment-specific review should capture the base token, accepted collateral, price feeds, thresholds and relevant administrative controls. Do not generalize from one Comet instance to every market carrying the Compound name.

The [Comet specification](https://github.com/compound-finance/comet/blob/main/SPEC.md#liquidation-functions) describes the absorb process and reserves. That workflow deserves its own accounting and incident treatment. A borrower losing collateral and a supplier facing unavailable withdrawal liquidity are not the same event. Ask the integration team to show how each appears in the ledger, notification system and support queue using a non-production fixture.

## Morpho Blue: the market ID is a risk decision

Morpho's market-creation documentation identifies a market using the loan token, collateral token, oracle, interest-rate model and liquidation loan-to-value, or LLTV. A second market with the same tuple cannot be created. Record all five fields with the market ID. A familiar token pair alone does not identify the market your application is using.

The [risk documentation](https://docs.morpho.org/learn/resources/risks/) describes oracle, liquidation, bad-debt and liquidity risks. It states that market LLTV is immutable and warns that lack of liquidity can delay withdrawal. Immutability narrows one kind of change; it does not establish that an oracle is correct, a collateral asset retains value or a lender can always exit.

Keep direct market supply separate from a curated vault allocation. A vault can introduce another decision-maker and another set of allocation or withdrawal assumptions. This article does not compare vault curators or treat a vault's advertised rate as the result of one market. If the buyer wants a vault integration, expand the review boundary before signing off.

For a synthetic test, prepare two records with the same loan and collateral tokens but different oracle addresses. Have the application reject a mismatch against the approved market record. That is a proposed acceptance check, not evidence that a particular frontend is vulnerable. It tests whether the integration preserves the exact risk decision made during diligence.

## Test the operational failures without depositing money

Use a local fixture, fork under controlled conditions or an approved test environment. Do not improvise a mainnet position to validate a screen. Define the expected state transitions first, then review contract behavior and integration code with the appropriate specialists.

| Scenario | Required application behavior | Evidence to retain |
|---|---|---|
| Market liquidity below requested withdrawal | Explain the unavailable amount without promising instant exit | Input snapshot, calculation and displayed message |
| Collateral price unavailable or stale | Apply an explicit hold or review policy | Oracle source, observation time and error class |
| Governance or configuration changes | Refresh assumptions and trigger the agreed review | Old/new values and responsible owner |
| Wrong deployment or market | Reject the operation before signing | Chain, address or market mismatch |
| Indexer disagrees with chain state | Show an unresolved state and reconcile | Block reference and source timestamps |
| Integration supplier is replaced | Rebuild position history from retained records | Export schema and reconciliation result |

Do not compare integrations using only successful RPC responses. Ask who maintains adapters, handles version changes and answers a disputed position calculation. Obtain a quote that separates integration engineering, ongoing monitoring, RPC/indexer services and independent review. No comparative cost or implementation-time estimate is established by this article.

The [DeFi infrastructure directory](/vendors/defi-infrastructure) helps locate protocol categories. The [oracle comparison](/blog/chainlink-vs-pyth-vs-redstone-oracle-providers) addresses a related dependency, while [onchain private credit](/blog/centrifuge-vs-maple-vs-goldfinch-onchain-private-credit) concerns a different lending model. Finish this shortlist with a deployment-specific risk record, not a brand-level safety score.
